Allies and friends,
The movement to protect children from the harms of transgender ideology continues to grow in success. Just recently, a federal judge blocked a rule change that would force doctors to refer for transgender interventions. Read more of the latest below!
Organizations representing over 75,000 physicians and healthcare professionals have signed the Doctors Protecting Children Declaration to urge U.S. medical institutions to halt the use of puberty blockers, cross-sex hormones, and transgender surgeries on minors. Thousands more individuals have signed representing over 58 countries, and tens of millions have viewed on social media. If you haven’t already, be sure to sign the Doctors Protecting Children Declaration today.
Sincerely,
The Biological Integrity Team
The American College of Pediatricians
Federal Judge Blocks Biden Admin Gender Rule After 15 States Sue
The Biden Administration’s Department of Health and Human Services made rule changes expanding sex discrimination in healthcare to gender discrimination, forcing doctors to adopt gender ideology in their practice. Fifteen states sued, and last week, a District Judge temporarily blocked enforcement of the rule.
Texas Supreme Court Upholds Law Protecting Minors from Transgender Interventions
In an 8-1 ruling, the Texas Supreme Court upheld the state’s law prohibiting transgender interventions on children as part of the “legislature’s express constitutional authority to regulate the practice of medicine.”
The one dissenter, Justice Lehrmann, called the law “cruel” because it prevents lifesaving treatment. In fact, all of the evidence suggests that such interventions harm, not help children.
American Principles Project Exposes Money Driving the Gender Industry
Recently, the American Principles Project released a report finding that the market for transgender drugs and surgeries was worth $4.4 billion in 2023. The report also found that some transgender surgery providers were making more than $100 million in revenue annually.
The financial interests at stake for providers of puberty blockers, cross-sex hormones, and surgeries should raise even more caution.
